services available on all working days from 8:00AM to 4:00PM

Special evening OPD facility available on specific days in a week from (5:00PM TO 7:00PM)

Various speciality clinic services including breast clinic , Head and neck clinic, Genitourinary, Gynaec oncology clinic, GIT clinic, chest clinic and other clinical services available with the aim of delivering the best possible updated treatment.

 Various OPD procedures such as bone marrow aspiration and biopsy, blood and blood product transfusions, central line care, dressings etc are being carried out in a well facilitated set up by well trained doctors and nursing staff.

Different chemotherapy protocols are being delivered on a day care basis for which department owns a ( 17 bedded) day care chemotherapy room with well trained staffs functioning from morning 9:00Am to 4:00pm on all working days.

Department of Medical Oncology is also equipped with an ICU which functions exclusively with well trained ICU nursing and supportive staff. for handling neutropenia and other oncological emergencies.

Department is updated with Bone marrow transplantation unit which handles both autologous and allogenic transplants , aiming at delivering utmost cost effective and high quality care to all the transplant patients.

 The department also has a well-functioning Clinical Research Unit (CRU) which hosts different types of projects (NOCI-BIRAC, HCC &

ICMR-HBCR). CRU also handles hospital based cancer registry and clinical trials , which offer a great opportunity for cancer patients in getting the latest treatment.

 The department of Medical oncology is the first in private sector, under the Kerala University of Health Sciences to get approval for an annual intake of DM seats per year. The department provides one of the best evidence based training in the subject with various other academic activities like clinical discussion, journal clubs, presentations and discussions.

 As this institute is a comprehensive cancer centre, alll the complicated oncology cases are discussed in detail for planning the best treatment in a multidisciplinary board consisting of medical oncologists, surgical oncologists, radiation oncologists, pathologists, radiologist

CAR T-Cell (Chimeric Antigen Receptor T-Cell) therapy is one of the most groundbreaking innovations in modern cancer treatment. This advanced form of immunotherapy modifies a patient’s own T-cells (critical immune cells) to identify and destroy cancer cells with remarkable precision. Unlike conventional treatments like chemotherapy or radiation that attack cancer directly, CAR T-Cell therapy empowers the body’s immune system to fight cancer at a cellular level. Designed primarily for haematologic malignancies such as Acute Lymphoblastic Leukaemia (ALL) and certain types of lymphomas, CAR T-Cell therapy has transformed outcomes for patients who previously had limited treatment options. The success story of Emily Whitehead—the first paediatric patient in the world to successfully undergo CAR T-Cell therapy at Children’s Hospital of Philadelphia (CHOP)—remains a global testament to its life-saving potential. Diagnosed with relapsed ALL, Emily was treated with an experimental CAR T protocol after conventional therapies failed. Thirteen years later,today she remains cancer-free, offering hope to thousands. Since then, over 35,000 patients worldwide have benefitted from this pioneering therapy. CAR T cell therapy involves collecting a patient’s T-cells, genetically engineering them in specialised labs to express synthetic receptors that recognise cancer cells, expanding them in large numbers, and re-infusing them into the patient. While it is a highly personalised and complex procedure, the therapy has shown cure rates of up to 60% in otherwise treatment-resistant leukaemia and lymphoma cases. Though side effects such as Cytokine Release Syndrome (CRS) and neurotoxicity require expert management, advances in clinical care have made these risks increasingly controllable. Amala Institute of Medical Sciences is proud to be at the forefront of cellular therapies in India. As the first centre in the country to introduce Tumour-Infiltrating Lymphocyte (TIL) Therapy (Another form of cell therapy) and the second in Kerala to offer CAR T-Cell therapy, Amala continues to set new standards in precision oncology. With state-of-the-art infrastructure, dedicated expertise, and a mission to offer cutting-edge care, Amala remains a trusted destination for advanced cancer therapies in India.